Former Adaptive Biotechnologies CSO Harlan Robins secured $15 million to launch a new startup focused on scientific AI training. The venture targets the gap between raw biological data and machine learning utility. By rethinking how models ingest complex science, Robins aims to accelerate drug discovery. Practitioners should watch for new standards in specialized biotech datasets.